PharmaSGP Holding Stock

PharmaSGP Holding EBIT 2024

PharmaSGP Holding EBIT

31.31 M EUR

Ticker

PSG.DE

ISIN

DE000A2P4LJ5

WKN

A2P4LJ

In 2024, PharmaSGP Holding's EBIT was 31.31 M EUR, a 27.08% increase from the 24.64 M EUR EBIT recorded in the previous year.

The PharmaSGP Holding EBIT history

YEAREBIT (undefined EUR)
2027e45.62
2026e38.84
2025e34.59
2024e31.31
202324.64
202217.78
202115.8
202014.63
201922.36
201819.55
201715.32

PharmaSGP Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into PharmaSGP Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PharmaSGP Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PharmaSGP Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PharmaSGP Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PharmaSGP Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PharmaSGP Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PharmaSGP Holding’s growth potential.

PharmaSGP Holding Revenue, EBIT and net profit per share

DatePharmaSGP Holding RevenuePharmaSGP Holding EBITPharmaSGP Holding Net Income
2027e139.77 M undefined45.62 M undefined0 undefined
2026e131.96 M undefined38.84 M undefined26.1 M undefined
2025e122.31 M undefined34.59 M undefined22.77 M undefined
2024e113.83 M undefined31.31 M undefined19.19 M undefined
2023101.1 M undefined24.64 M undefined16.4 M undefined
202285.82 M undefined17.78 M undefined11.95 M undefined
202165.34 M undefined15.8 M undefined10.69 M undefined
202063.25 M undefined14.63 M undefined10.64 M undefined
201962.57 M undefined22.36 M undefined16.71 M undefined
201860.6 M undefined19.55 M undefined14.73 M undefined
201753.06 M undefined15.32 M undefined11.78 M undefined

PharmaSGP Holding stock margins

The PharmaSGP Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PharmaSGP Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PharmaSGP Holding.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PharmaSGP Holding's sales revenue. A higher gross margin percentage indicates that the PharmaSGP Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PharmaSGP Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PharmaSGP Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PharmaSGP Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PharmaSGP Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PharmaSGP Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PharmaSGP Holding Margin History

PharmaSGP Holding Gross marginPharmaSGP Holding Profit marginPharmaSGP Holding EBIT marginPharmaSGP Holding Profit margin
2027e90.64 %32.64 %0 %
2026e90.64 %29.43 %19.78 %
2025e90.64 %28.28 %18.61 %
2024e90.64 %27.51 %16.86 %
202390.64 %24.37 %16.22 %
202289.48 %20.71 %13.93 %
202190.07 %24.18 %16.36 %
202090.19 %23.14 %16.82 %
201990.62 %35.74 %26.7 %
201889.27 %32.26 %24.31 %
201791.27 %28.87 %22.21 %

PharmaSGP Holding Aktienanalyse

What does PharmaSGP Holding do?

PharmaSGP Holding SE is a leading European company specializing in the marketing of over-the-counter and natural pharmaceuticals. The company was founded in 2009 and is headquartered in Gräfelfing near Munich. The history of PharmaSGP began with the vision of founder and CEO Alexander Kurz, who believed that many people were looking for natural alternatives to pharmaceuticals. Kurz founded PharmaSGP with the goal of developing natural health products that help people improve their health and well-being. PharmaSGP's business model focuses on the marketing of over-the-counter and natural pharmaceuticals through pharmacies, drugstores, and online sales. The company has a strong presence in Europe and is also expanding into other regions worldwide. PharmaSGP is divided into three divisions: Consumer Healthcare, Medical Devices, and Healthcare Services. The Consumer Healthcare division offers natural health products and dietary supplements targeting consumers. The company has developed a wide range of products specifically tailored to the needs of people at different stages of life, from pregnancy and breastfeeding to old age. In the field of medical devices, PharmaSGP focuses on the development and marketing of innovative medical devices and technologies tailored to the needs of healthcare professionals. The company has developed a range of medical devices such as medication dispensers or blood glucose meters to facilitate disease treatment. In the Healthcare Services division, the company also offers services such as medical consulting and patient management. This involves holistic patient care, offering various services to ensure effective and comprehensive treatment. PharmaSGP also has an impressive range of products covering various health areas. There are products for dietary supplementation, sleep support, pain therapy, and cold relief, to name just a few. One of PharmaSGP's most well-known products is Yokebe, a natural meal replacement that can help reduce weight. The company is committed to ensuring the quality of its products and therefore works closely with scientists and healthcare professionals to ensure that all products are based on current scientific knowledge and studies. In summary, PharmaSGP is an innovative company focused on the marketing of natural and over-the-counter pharmaceuticals. It has developed a wide range of products and services specifically tailored to the needs of consumers and healthcare professionals. The company is committed to continuously improving the quality of its products and services and works closely with scientists and healthcare professionals to ensure comprehensive patient care. PharmaSGP Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing PharmaSGP Holding's EBIT

PharmaSGP Holding's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PharmaSGP Holding's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PharmaSGP Holding's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PharmaSGP Holding’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PharmaSGP Holding stock

How much did PharmaSGP Holding achieve in EBIT for the current year?

In the current year, PharmaSGP Holding has achieved an EBIT of 31.31 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company PharmaSGP Holding.

How has the EBIT of PharmaSGP Holding developed in recent years?

The EBIT of PharmaSGP Holding has increased by 27.08% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company PharmaSGP Holding?

The EBIT of PharmaSGP Holding is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does PharmaSGP Holding pay?

Over the past 12 months, PharmaSGP Holding paid a dividend of 0.49 EUR . This corresponds to a dividend yield of about 2.02 %. For the coming 12 months, PharmaSGP Holding is expected to pay a dividend of 0.59 EUR.

What is the dividend yield of PharmaSGP Holding?

The current dividend yield of PharmaSGP Holding is 2.02 %.

When does PharmaSGP Holding pay dividends?

PharmaSGP Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PharmaSGP Holding?

PharmaSGP Holding paid dividends every year for the past 0 years.

What is the dividend of PharmaSGP Holding?

For the upcoming 12 months, dividends amounting to 0.59 EUR are expected. This corresponds to a dividend yield of 2.45 %.

In which sector is PharmaSGP Holding located?

PharmaSGP Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von PharmaSGP Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PharmaSGP Holding from 7/1/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did PharmaSGP Holding pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of PharmaSGP Holding in the year 2023?

In the year 2023, PharmaSGP Holding distributed 0.45 EUR as dividends.

In which currency does PharmaSGP Holding pay out the dividend?

The dividends of PharmaSGP Holding are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PharmaSGP Holding

Our stock analysis for PharmaSGP Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaSGP Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.